Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Laura Chico from Wedbush maintained a Buy rating on the stock and has a $41.00 price target.
Laura Chico’s rating is based on the progress and potential of Viridian Therapeutics’ development programs. The company is on track with its key projects, including the anticipated submission of the veligrotug BLA by the second half of 2025, which is expected to lead to a US launch in the second half of 2026. Additionally, the REVEAL-1 and REVEAL-2 studies for VRDN-003 are progressing as planned, with results expected in the first half of 2026. The company also holds a strong cash position of $637 million, providing a runway into the second half of 2027, which supports its ongoing pipeline efforts.
Despite challenges faced by competitors, such as Tepezza, Viridian’s offerings, like veligrotug and VRDN-003, are seen as having advantages, including shorter treatment durations. The company’s financial adjustments and strategic planning have resulted in a revised target price of $41, reflecting an attractive entry point relative to current trading levels. Overall, the combination of a robust pipeline, strong financial position, and strategic advancements underpins the Buy rating for Viridian Therapeutics.
In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $41.00 price target.